LXEO
NASDAQLexeo Therapeutics Inc.
News25/Ratings11
News · 26 weeks54+25%
2025-10-262026-04-19
Mix2890d
- Insider11(39%)
- Other10(36%)
- SEC Filings5(18%)
- Leadership2(7%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- INSIDERSEC Form 4 filed by Townsend Richard Nolan4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECSEC Form 10-K filed by Lexeo Therapeutics Inc.10-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsSUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration St
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- INSIDERChief Executive Officer Townsend Richard Nolan was granted 2,623 shares, increasing direct ownership by 0.67% to 395,106 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel was granted 5,930 shares, increasing direct ownership by 5% to 131,390 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- PRLexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to resha
- INSIDERChief Operating Officer Otero Jose Manuel sold $19,294 worth of shares (3,016 units at $6.40), decreasing direct ownership by 2% to 125,460 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan sold $64,924 worth of shares (10,173 units at $6.38), decreasing direct ownership by 3% to 392,483 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERAmendment: Chief Operating Officer Otero Jose Manuel sold $6,684 worth of shares (721 units at $9.27), decreasing direct ownership by 1% to 63,476 units (SEC Form 4)4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECSEC Form 144 filed by Lexeo Therapeutics Inc.144 - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- INSIDERChief Medical Officer Bhalla Narinder Pal was granted 49,500 shares (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- INSIDERChief Financial Officer Tamayo Louis Edward was granted 44,665 shares, increasing direct ownership by 99% to 89,665 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan was granted 161,665 shares, increasing direct ownership by 67% to 402,656 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel was granted 65,000 shares, increasing direct ownership by 102% to 128,476 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bhalla Narinder Pal3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryNEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY. Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fireside chat on Thursday, February 26, 2026 at 10:40 a.m. ET (virtual). The events will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of th
- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)